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ABSTRACT
Nicorandil (SG75) is a potent K-channel activator with an additional nitro moiety.
In the present study we investigated the potential mechanisms (K-channel activa-
tion and nitric oxide [NO] release) for the effects of nicorandil on isolated perfused
rat hearts during total global ischemia using 31P-nuclear magnetic resonance. After
a 10-min control perfusion, hearts were subjected to treatment with nicorandil-
containing (100, 300, or1000 µM) buffer for10 min,15 min oftotal global ischemia,
and 30 min of reperfusion. At high dose (103 M), nicorandil reduced ATP depletion
during ischemia by 26% compared with untreated hearts. Blockade of K channels
by glibenclamide prevented this protective effect. At all doses (104 to 103 M),
nicorandil reduced the accumulation of protons during ischemia compared with
untreated hearts (pH 6.22  0.03 vs. 6.02  0.05 in untreated hearts at the end of
ischemia). Thiseffectwas preserved afterblockade ofK
channelsby glibenclamide.
Hearts treated with nitroglycerine before ischemia also showed reduced proton ac-
cumulation. Therefore, NO release accompanied by increased coronary ﬂow before
ischemia, which is caused by the nitro moiety of nicorandil and nitroglycerine treat-
ment, results in reduced proton accumulation. During reperfusion, a pro-arrhythmic
effect was observed in hearts treated with the nonpharmacologically high dose of
nicorandil (1000 µM). Thus, we conclude that the effects of nicorandil are caused
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by the simultaneous action of both mechanisms K-channel activation and NO re-
lease. The activation of K channels prevents deterioration of ATP during ischemia,
whereas NO release and increased coronary ﬂow reduce the accumulation of pro-
tons—and thus the decrease in pH—during ischemia.
Key Words: Ischemia; K-channel activation; Magnetic resonance spectroscopy;
Nicorandil; NO release; Reperfusion
INTRODUCTION
Maintenance of myocardial ion homeostasis involves
both numerous cation transport systems and a high ener-
getic state of the cardiomyocytes. As long as the heart is
in stable metabolic condition, the K
 channels keep the
balance of high intracellular and low extracellular K
concentrations. Ischemic stress leads to an increase of the
ADP/ATP ratio, which results in closing of the K chan-
nels, an increase of inorganic phosphate, and depolariza-
tion of the cardiomyocytes. Next, massive Ca2 inﬂux
will occur and cause ischemic injury to the cell (1).
Beneﬁcial effects of K-channel activators in the heart
have been shown under ischemic condition. Activation
of the K channels causes reduced sensitivity to lowered
ATP levels (2). Depolarization is attenuated or prevented
in hearts treated with K-channel activators, which low-
ers Ca2 inﬂux (3,4) and the extent of ischemic injury.
A variety of K-channel activators has been studied to
date,and allof themlower blood pressurein hypertensive
patients. Nicorandil (N-(2-hydroxyethyl)nicotinamideni-
trate, SG 75) is the most effective K-channel opener in
comparison with other K
-channel openers of the nico-
tinamide type (1). In addition, nicorandil may be beneﬁ-
cial for the treatment of unstable angina pectoris (5–11).
The nicorandil molecule holds two moieties that might
exert beneﬁcial effects during ischemia. Nicorandil acti-
vates K channels through its nicotinamide structure and
acts as a potent nitrate by its nitro group. The aims of
this study were to deﬁne the effects of nicorandil during
control perfusion, ischemia, and reperfusion in the iso-
lated rat heart over a wide dosage range beyond clinically
used dosages and to elucidate whether the mechanism
of the protective effect of nicorandil during ischemia are
related to alterations in myocardial energetics and intra-
cellular pH.
MATERIALS AND METHODS
Isolated Rat Heart Preparation
Male Wistar rats (340–360 g) were anesthetized by
intraperitoneal injection of 40 mg sodium pentobarbital.
A transverse laparotomy and a left and a right anterolat-
eral thoracotomy were performed. The heart was rapidly
excised and immersed in ice-cold buffer. The aorta was
dissected free and mounted onto a cannula attached to a
perfusion apparatus, as previously described (12). Retro-
grade perfusion of the heart with oxygenated Krebs-
Henseleit buffer was started in the Langendorff mode at
a constant temperature of 37°C and a coronary perfusion
pressure of 100 mm Hg. The investigation conforms to
the NIH guidelines for the care and use of laboratory ani-
mals and was approved by the local authorities (Regier-
ung von Unterfranken).
Cardiac Performance Measurements
A small ﬂexible polyethylene tube was pierced
through the apex of the left ventricle to allow drainage
of ﬂow from Thebesian veins. A water-ﬁlled latex bal-
loon was inserted through an incision in the left atrial
appendage, via the mitral valve, and secured by a liga-
ture. The volume of the balloon was adjusted to maintain
an end-diastolic pressure of 8–11 mm Hg. The balloon
was connected to a Statham pressure transducer (Gould
Instruments, Glen Burnie, MD) via a small-bore polyeth-
ylene tube for continuous measurement of left ventricular
pressures and heart rate on a four-channel graphic re-
corder (Watanabe, Tokyo, Japan). Performance was esti-
mated as rate-pressure product (mm Hg/min), that is, the
product of heart rate (min1), and left ventricular devel-
oped pressure (mm Hg), that is, the difference of systolic
and diastolic pressure. Coronary ﬂow was measured by
an ultrasound ﬂowmeter (Transonic Systems Inc., Ithaca,
NY). The time for onset of ischemic contracture was




The perfused hearts were placed in a 20-mm outer di-
ameter nuclear magnetic resonance (NMR) sample tube
(Wilmad, Buena, NJ) and inserted into a 31P- and 23Na-
NMR probe head (Paul Morris Inc., Gloucester, Canada)ORDER                        REPRINTS
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that was seated in the bore of a superconducting super-
wide-bore (150 mm) 7.05-T magnet (Oxford Instru-
ments, Oxford). The probe head held two replaceable
coils with 20-mm inner diameter for 31P at 121.44 MHz
and 30-mm inner diameter for 23Na at 79.353 MHz.
A Bruker AM 300 NMR console (Bruker, Rheinstet-
ten, Germany) was used for acquisition of NMR spectra.
Each radiofrequency coil was tuned and matched before
each experiment. Before the 31P-NMR measurement, the
magnet was shimmed with a 14-channel Bruker Shim
Supply to maximum area of the free induction decay of
the 23Na signal, which resulted in a linewidth of 8 to 11
Hz for a single-pulse 23Na-NMR spectrum.
For
31P-NMR measurements, 152 scans were averaged
with a pulse length of 37 µsec (pulse angle of 45 degrees)
and an interpulsedelayof 1.93sec, yieldingonespectrum
in5 min.Free induction decayswere exponentially multi-
plied with a line broadening of 20 Hz, Fourier trans-
formed, and the phase was corrected interactively. For
each experiment, 13 consecutive 31P-NMR spectra were
recorded.
Intracellular pH of all spectra was calculated from the
chemical shift difference between inorganic phosphate
and phosphocreatine, as previously described (13). The
resonance areas corresponding to ATP, phosphocreatine,
inorganic phosphate, and phosphate monoesters were in-
tegrated by Bruker DISNMR89 integration routine. In
each 31P-NMR experiment, the area of the γ-P-ATP reso-
nance of the ﬁrst spectrum was set arbitrarily to 100%
and used as a reference value for all resonances in the
set of
31P-NMR spectra obtained in a given protocol. Ar-
Table 1
Perfusion Scheme for the Various Groups
Control Period, Treatment Period, Gobal Ischemia, Reperfusion,
Group n 10 min 10 min 15 min 30 min
Untreated 9 Krebs-Henseleit Krebs-Henseleit No ﬂow Krebs-Henseleit
Nico 100 10 Krebs-Henseleit 100 µM nicorandil No ﬂow 100 µM nicorandil
Nico 300 11 Krebs-Henseleit 300 µM nicorandil No ﬂow 300 µM nicorandil
Nico 1000 10 Krebs-Henseleit 1000 µM nicorandil No ﬂow 1000 µM nicorandil
Gli 0 9 Krebs-Henseleit 1 µM glibenclamide No ﬂow 1 µM glibenclamide
Gli 100 9 Krebs-Henseleit 100 µM nicorandil  1 µM No ﬂow 100 µM nicorandil  1 µM
glibenclamide glibenclamide
Gli 300 9 Krebs-Henseleit 300 µM nicorandil  1 µM No ﬂow 300 µM nicorandil  1 µM
glibenclamide glibenclamide
Gli 1000 9 Krebs-Henseleit 1000 µM nicorandil  1 µM No ﬂow 1000 µM nicorandil  1 µM
glibenclamide glibenclamide
Nitro 100 9 Krebs-Henseleit 100 µM nitroglycerine No ﬂow 100 µM nitroglycerin
eas were corrected for partial saturation (1.12 for phos-
phocreatine, 1.08 for inorganic phosphate), and concen-
trations were calculated assuming 11.2 mM ATP content
in the heart (14).
Pharmaceutical Agents and Buffer
Solutions
Hearts were perfused with modiﬁed Krebs-Henseleit
solution containing NaCl (118.0 mM), KCl (4.7 mM),
MgSO4 (1.2 mM), CaCl2 (1.75 mM), EDTA (0.5 mM),
NaHCO3 (25.0 mM), and glucose (11.0 mM) dissolved
in demineralized water (Fresenius, Bad Homburg, Ger-
many). All ingredients were purchased from Sigma
Chemie (Deisenhofen, Germany) and used without fur-
ther puriﬁcation. The perfusion solution was continu-
ously equilibrated with 95% O2 and 5% CO2 to maintain
a pH of 7.4. Agents were purchased from or kindly pro-
vided by the following: glibenclamide (Sigma Chemie),
nicorandil and propanediol (Merck, Darmstadt, Ger-
many), and nitroglycerine (G. Pohl-Boskamp, Hohen-
lockstedt, Germany).
A total of 21.1, 63.5, or 211.2 mg of nicorandil per
liter Krebs-Henseleit buffer was dissolved to yield buffer
concentrations of 100, 300, and 1000 µM nicorandil, re-
spectively. A stock solution of glibenclamide, a selective
blocker of ATP-dependent K channels (15–17), dis-
solved in propanediol, was added to Krebs-Henseleit
buffer (1 ml stock solution to 1 l Krebs-Henseleit buffer)
to yield a concentration of 1 µM glibenclamide. Nitro-
glycerine was added as purchased to a modiﬁed Krebs-ORDER                        REPRINTS
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Henseleit buffer (NaCl 114.6 mM, glucose 4.8 mM) to
result in the same concentrations for NaCl and glucose
as the Krebs-Henseleit buffer listed above.
Protocol
The protocols for perfusion of each group are listed
in Table 1. Hearts underwent 10 min of perfusion with
Krebs-Henseleit buffer as the control period, followed by
10 min of perfusion with drug-containing buffer (or
Krebs-Henseleit buffer for untreated group), before 15
min of total global normothermic ischemia and 30 min
of reperfusion with drug-containing buffer. Four groups
of hearts were studied:
1. Untreated hearts: perfused with Krebs-Henseleit
buffer (Untreated);
2. Nicorandil-perfused hearts: three subgroups, per-
fused with buffer containing 100 µM (Nico 100),
300 µM (Nico 300), or 1000 µM nicorandil (Nico
1000);
3. Glibenclamide-perfused hearts: four subgroups,
perfusedwith buffer containing 1µM glibenclam-
ide (Gli 0), or 100 µM nicorandil  1 µM gliben-
clamide (Gli 100), or 300 µM nicorandil  1 µM
glibenclamide (Gli 300), or 1000 µM nicorandil
 1 µM glibenclamide (Gli 1000);
4. Nitroglycerine-perfused hearts: perfused with
buffer containing 100 µM nitroglycerine (Nitro
100).
An additional group of hearts was treated with Krebs-
Henseleit buffer plus propanediol to exclude effects of
propanediol. Data not shown.
Statistical Analysis
The values of the individual hearts were averaged for
each parameter to obtain mean values for each group.
Data from the various groups were compared for each
parameter by factorial analysis of variance followed by
Scheffe’s F-test (18), unless otherwise stated. Calcula-
tions were performed with the StatView SEGraphics,
Statistic Utility (Abacus Concepts, Berkeley, CA). Data
are presented as means  SE.
RESULTS
Control Period
At all concentrations, nicorandil caused an increase of
coronary ﬂow (Fig. 2a) by 73  7, 55  13, and 45 
Figure 1.
31P-NMR spectra of untreated (left column) and
1000 µM nicorandil-treated (right column) hearts during con-
trol period, at the end of ischemia, and at the end of reperfusion.
Pi, inorganic phosphate; PCr, phosphocreatine.
9% (p  0.05 vs. Untreated) in hearts perfused with 100,
300, and 1000 µM nicorandil, respectively. Glibenclam-
ide did not alter coronary ﬂow signiﬁcantly. The combi-
nation of nicorandil and glibenclamide increased coro-
nary ﬂow (32  4,* 61  8,* and 71  11% for 100,
300, and 1000 µM nicorandil  1 µM glibenclamide,
respectively; *p  0.05 vs. 1 µM glibenclamide). Perfu-
sion of hearts with buffer containing 100 µM nitroglycer-
ine increased coronary ﬂow from 20.7  0.8 to 24.2 
0.8* ml/min (*p  0.05), that is, by 27  4%.
As summarized in Table 2, lower concentrations of
nicorandil (100 and 300 µM) led to an increase of the
rate-pressure product due to increased left ventricular de-
veloped pressure, which presumably is due to the turgor
effect. The turgor, or ‘‘garden hose,’’ effect describes the
phenomenon that the myocardial wall is stretched in pro-ORDER                        REPRINTS
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Figure 2. Parameters of perfusion and mechanical performance in untreated hearts and hearts treated with 100, 300, or 1000 µM
nicorandil during control perfusion, treatment, ischemia, and reperfusion. (a) Coronary ﬂow (ml/min), (b) end-diastolic pressure
(mm Hg), and (c) heart rate (min1).
portion to coronary artery perfusion pressure. In the iso-
lated heart setting, therefore, as coronary ﬂow (and perfu-
sion pressure) increases, end-diastolic pressure increases
in parallel. Because of the Starling mechanism, this then
leads to increased left ventricular developed pressure due
to increased preload. For high-dose nicorandil (1000
µM), a negative inotropic effect offsets the effect of in-
creased ﬂow on performance. Therefore, no net effect on
the rate-pressure product occurred. The rate-pressure
product also increased in hearts perfused with nicor-
andil  glibenclamide. However, the negative inotropic
effect of high nicorandil was not seen in these hearts.
Hearts perfusedwith 100µMnitroglycerine similarly had
increased rate-pressure products. The heart rate was not
affected by perfusion with either nicorandil or nicoran-
dil  glibenclamide nor by perfusion with nitroglycerine.
Therefore, all changes in rate-pressure product directly
reﬂect changes in left ventricular developed pressure.
During the control period, end-diastolic pressure did
not change before and during treatment with nicorandil.
Additional treatment with glibenclamide or treatment
with nitroglycerine alone had no effect on heart rate, end-
diastolic and left ventricular developed pressure, and thus
the rate-pressure product. During the control period, nic-
orandil, glibenclamide, and nitroglycerine had no effect
on intracellular pH or concentrations of 31P metabolites.
Typical spectra of untreated heartsand heartstreated with
1000 µM nicorandil are given in Fig. 1.ORDER                        REPRINTS
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Table 2
Mechanical Function of Hearts Expressed as Heart Rate (HR, min1), Left Ventricular Developed Pressure (LVDP, ml/min),
and Rate-Pressure Product (RPP, 10
3 mm Hg/min) During Control Perfusion Before and During Treatment
HR LVDP RPP
Control Treatment Control Treatment Control Treatment
Untreated 321  7 323  69 7  59 2  4* 31.0  1.9 29.9  1.5
Nico 100 326  5 321  69 5  4 109  4* 30.9  1.0 35.3  1.5*
Nico 300 319  5 324  7 105  5 114  5 32.7  1.7 35.8  1.4*
Nico 1000 321  8 327  79 8  29 2  3* 31.6  1.2 30.1  1.1
Gli 0 317  7 321  10 87  57 8  6* 27.5  1.8 24.8  1.8*
Gli 100 333  8 345  69 1  3 100  5 30.6  1.6 34.3  1.5*
Gli 300 319  7 325  49 4  5 112  6* 29.7  1.5 36.3  1.7*
Gli 1000 322  10 332  89 1  7 116  7* 29.6  3.1 39.6  3.3*
Nitro 100 323  8 311  99 7  5 109  6* 31.2  1.6 33.8  1.5*
*p  0.05 Control vs. Treatment.
Ischemia
During total global ischemia, all hearts were arrested
within 2.5 min. Therefore, heart rate, left ventricular de-
veloped pressure, and rate-pressure product were all zero.
During ischemia, end-diastolic pressure gradually in-
creased in all groups (Table 3). The increase of end-dia-
stolic pressure was slower in high-dose nicorandil com-
pared with untreated hearts. Therefore, the time for onset
of ischemic contracturewas signiﬁcantlydelayed inhigh-
dose nicorandil (12.1  0.6, 12.0  0.8, 11.6  0.9, and
14.8  0.8* min for Untreated and 100, 300, and 1000
µM nicorandil; *p  0.05). Although there was no effect
Table 3
End-Diastolic Pressure (EDP), Time to Ischemic Contracture (TIC), ATP, Inorganic Phosphate (Pi), and Intracellular pH
at the End of Ischemia
EDP TIC ATP Pi
(mm Hg) (min) (mM) (mM) pH
Untreated 23  6 12.1  0.6 3.92  0.34 28.34  1.90 6.02  0.05
Nico 100 23  4 12.0  0.8 3.92  0.56 28.56  1.12 6.28  0.12*
Nico 300 21  4 11.6  0.9 4.26  0.56 30.69  1.79 6.18  0.12*
Nico 1000 12  2 14.8  0.8* 5.71  0.56* 23.63  1.12* 6.22  0.03*
Gli 0 23  5 12.9  1.5 4.37  0.56 30.58  0.78 6.03  0.03
Gli 100 45  5† 7.0  0.9*† 3.81  0.34 35.06  1.12 6.23  0.04*†
Gli 300 43  3† 8.3  0.7*† 3.47  0.45 31.36  1.23 6.23  0.05*†
Gli 1000 43  6† 8.6  1.1*† 3.14  0.45 36.40  1.34 6.20  0.05*†
Nitro 100 31  4 8.8  0.8* 2.69  0.45* 32.48  1.46 6.15  0.04*
*p  0.05 vs. Untreated.
†p  0.05 vs. Gli 0.
of 1 µM glibenclamide on the time for onset of ischemic
contracture, hearts perfused with nicorandil  gliben-
clamide showed a signiﬁcantly faster increase of end-dia-
stolic pressure (12.9  1.5, 7.0  0.9,* 8.3  0.7,* and
8.6  1.1* min for 1 µM glibenclamide and 100, 300,
and 1000 µM nicorandil  1 µM glibenclamide, respec-
tively; *p  0.05). Nitroglycerine-treated hearts showed
a faster increase of end-diastolic pressure than untreated
or 100 µM nicorandil-treated hearts (time for onset of
ischemic contracture 8.8  0.8 min, p  0.05 vs. Un-
treated, 100 µM nicorandil).
During ischemia, phosphocreatine declined rapidly
in all groups. Within 5 min, phosphocreatine levels de-ORDER                        REPRINTS
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Figure 3. Parameters of 31P metabolites in untreated hearts and hearts treated with 100, 300, or 1000 µM nicorandil during control
perfusion, treatment, ischemia, and reperfusion. (a) Phosphocreatine, (b) ATP, and (c) inorganic phosphate. (All values are given
as mM.)
creased to less than 20% of control perfusion and fell to
zero until the end of ischemia (Fig. 3a). During ischemia,
ATP declined in all groups. Depletion of ATP was re-
duced only in hearts treated with 1000 µM nicorandil (p
 0.05 Nico 1000 vs. Untreated). Here, ATP at the end
of ischemia was signiﬁcantly higher (51  5% of pre-
ischemia, *p  0.05 vs. Untreated) than in untreated
hearts (35  3%) orhearts treated with low-dose nicoran-
dil (35  5% in 100 µM, 38  5% in 300 µM nicorandil;
Fig. 3b). Hearts treated with nicorandil  glibenclamide
showed depletion of ATP as in the untreated group. Inor-
ganic phosphate increased rapidly during early ischemia,
with a more gradual rise there after (Fig. 3c). Reduced
ATP depletion of hearts treated with 1000 µM nicorandil
was reﬂected by lower inorganic phosphate levels at the
end of ischemia (Table 3). Treatment of hearts with nitro-
glycerine did not inﬂuence high-energy phosphate deple-
tion during ischemia.
In all groups intracellular pH fell rapidly during isch-
emia (Fig. 4). In hearts treated with nicorandil, intracellu-ORDER                        REPRINTS
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Figure 4. Intracellular pH value from untreated hearts and
hearts treated with 100 µM nicorandil or 100 µM nitroglycerine
during control, treatment, ischemia, and reperfusion.
lar acidosis was attenuated at all dosages (6.02  0.05,
6.28  0.12,* 6.18  0.02,* and 6.22  0.03* for Un-
treated and 100, 300, and 1000 µM nicorandil, respec-
tively; *p  0.05 vs. Untreated). This was also observed
in hearts treated with nicorandil  glibenclamide (6.23
Table 4
End-Diastolic Pressure (EDP), Left Ventricular Developed Pressure (LVDP), and Rate-Pressure Product (RPP)
at the End of Reperfusion
EDP LVDP LVDP RPP
(mm Hg) (mm Hg) (% of control) (103 mm Hg/min) pH
Untreated 23  67 6  77 2  11 23.2  2.3 7.13  0.02
Nico 100 23  48 2  98 3  8 26.5  3.2 7.16  0.00
Nico 300 21  49 2  68 8  5 24.5  4.3 7.14  0.02
Nico 1000 12  21 2  11 13  12* 3.7  3.5* 7.15  0.01
Gli 0 23  54 9  13 52  13 15.1  4.4 7.1  0.03
Gli 100 45  55 6  14 58  12 17.6  4.8 7.13  0.01
Gli 300 43  32 9  83 2  10* 9.6  2.8 7.09  0.02
Gli 1000 43  63 1  10 37  13* 9.8  3.9 7.08  0.03
Nitro 100 31  45 8  14 57  14 14.2  3.7 7.14  0.02
*p  0.05 vs. Untreated.
 0.04, 6.23  0.05, and 6.20  0.05 for 100, 300, and
1000 µM nicorandil  1 µM glibenclamide; p  0.05
vs. Gli 0). In hearts treated with nitroglycerine, proton
accumulation was also attenuated (6.15  0.04; p  0.05
vs. Untreated).
Reperfusion
During reperfusion, coronary ﬂow returned to control
values in the untreated, glibenclamide-treated, and low-
dose nicorandil groups. Hearts treated with 1000 µM nic-
orandil had a signiﬁcantly higher coronary ﬂow (Fig. 2a)
during reperfusion. Untreated hearts and hearts perfused
with low-dose nicorandil (100 and 300 µM) resumed me-
chanical function within the ﬁrst 5 min of reperfusion.
End-diastolic pressure declined during reperfusion but
did not fully recover (Table 4). In these groups, left ven-
tricular developed pressure returned to approximately
80% of control values at the end of reperfusion. Because
the heart rate was not affected in the groups mentioned
above, rate-pressure product returned to 80  8, 76  9,
and 67  11% of untreated, treated, 100 and 300 µM
nicorandil-treated hearts, respectively (Table 4).
At 1000 µM nicorandil, 9 of 10 hearts ﬁbrillated
during reperfusion. Here, the end-diastolic pressure re-
mained elevated at extremely high levels, whereas heart
rate, left ventricular developed pressure, and rate-pres-
sure product did not recover.
Hearts treated with nitroglycerine showed a tendency
for reduced recovery of left ventricular developed pres-ORDER                        REPRINTS
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sure (57  14% of control) than the untreated hearts
(72  11% of control) or 100 µM nicorandil-treated
hearts (83  8% of control). However, recovery of left
ventricular developed pressure in 100 µM nicorandil 
1 µM glibenclamide-treated hearts (58  12% of control)
was similar to nitroglycerine-treated hearts. In hearts
treated with 300 or 1000 µM glibenclamide, recovery of
left ventricular developed pressure was reduced in com-
parison with untreated hearts (Table 4).
During reperfusion, phosphocreatine recovered
quickly in all groups (Fig. 3a). In nicorandil-treated
hearts there was an initial overshoot above control values
leveling off at control concentrations, whereas gliben-
clamide-treated and nitroglycerine-treated hearts recov-
ered to control values without initial overshoot. ATP
recovered to 50% of control value in all groups. Inor-
ganic phosphate levels remained elevated above control
levels (Fig. 3c). During reperfusion, the pH recovered in
all groups to a mean value of 7.11  0.01 with no differ-
ences among the groups (Table 4).
DISCUSSION
Effects of Nicorandil and Nitroglycerine
on Coronary Flow
In all treated groups, an increase of coronary ﬂow was
observed as reported previously (19–23). This is due to
relaxation of the vascular smooth muscle by nicorandil.
To differentiate whether this effect was caused by the
nitric oxide (NO) donor effect or the K
 channel activa-
tion, we compared two sets of experiments with nitro-
glycerine or glibenclamide. Glibenclamide (1 µM) is an
effective blocker of ATP-dependent K
 channels (24)
and is reported to be effective in experiments with croma-
kalim and pinacidil on smooth muscle cells (25–27). Our
results (Fig. 2a) suggest two independent mechanisms for
the vasodilatory effect of nicorandil. Stimulation of the
guanylate cyclase by NO causes an increase of cGMP
levels and hyperpolarization of the smooth muscle cell
membrane (28). However, the nitro moiety causes
stronger effects than the K-channel activation. As re-
ported by Holzmann (6) and Kukovetz et al. (28), cGMP
levels and relaxation of the vascular smooth muscle was
enhanced by nicorandil compared with other nitro com-
pounds. This suggests anadditional relaxingeffect of nic-
orandil, which isindependent of the production of cGMP,
as supported by the work of Shono et al. (29). A direct
inhibition of the Ca2 inﬂux in the cell by nicorandil was
discussed by Taira et al. (30), because an increased level
of cytosolic cGMP (31) causes a decrease of cytosolic
Ca2 levels in smooth muscle (32,33). However, the ef-
fect of nicorandil on heart and vascular muscle (9,30), as
well as the relaxation of rabbit coronary arteries (34), is
different from primary Ca2 channel antagonists. Kuko-
vetz et al. (28) used methylene blue for the nonspeciﬁc
inhibition of guanylate cyclase and cGMP formation by
nitro compounds and antagonized the effects of nicoran-
dil on cGMP up to a concentration of 47 µM. The re-
laxing effects of nicorandil were still 55% above control,
which was shown to be induced by hyperpolarization.
In contrastto nitroglycerine, nicorandilcauses dilation
of large and small coronary vessels (20,35,36). Whereas
nitroglycerine has high potential for dilatation of large
vessels, its effect on small coronary resistance vessels is
minimal (37). Thus, Hashimoto et al. (36) and Berdeaux
et al. (20) classiﬁed the action of nicorandil on small ves-
sels as response to hyperpolarization of the membranes,
whereas large vessels are dilated by NO release.
Effects of Nicorandil with and without K-
Channel Blockade by Glibenclamide and
Nitroglycerine on Mechanical Function
Conﬂicting reports on positive inotropic effects of nic-
orandil in high concentrations in anesthetized dogs (38)
and negative inotropic effect (39,40) due to shortening
of the action potential are reported in the literature. Our
data show an increase of mechanical performance during
low (100 µM) and medium (300 µM) dose nicorandil
treatment. Because in the constant pressure model me-
chanical performance is directly linked to coronary ﬂow,
we suggest that these changes are caused by a turgor ef-
fect. High dose (1000 µM) nicorandil, however, causes
depression of mechanical performance (39) besides an
increased coronary ﬂow as reported previously. There-
fore, reduced mechanical performance might be a result
of the mild negative inotropic effect of nicorandil due to
shortening of the action potential (22,41). A similar dose
dependence was found for low versus high doses of cro-
makalim (42). Blockade of K channels with glibenclam-
ide under nicorandil treatment had no effect on the turgor
effect. However, the depression of mechanical perfor-
mance (left ventricular developed pressure and rate-pres-
sure product) due to a negative inotropic effect of high
dose nicorandil was prevented. During reperfusion, ﬂow
was comparable in nitroglycerine- and nicorandil- (100
µM) treated hearts. However, rate-pressure product was
higher in nicorandil-treated hearts. This ﬁnding supports
our suggestion that the action potential is shortened,ORDER                        REPRINTS
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whereas the nitro effect does not change hyperpolariza-
tion in cardiac muscle. Kukovetz et al. (28) were able to
show the same two effects of nicorandil, hyperpolariza-
tion, and cGMP stimulation in bovine coronary vascular
smooth muscle. In our study, we found no effect of nico-
randil on heart rate and end-diastolic pressure.
Effects of Nicorandil on 31P Metabolism
and Proton Accumulation
Concentrations of
31P-NMR visible metabolites were
equal in all groups during the control period. There was
no change in 31P metabolites when the buffer was
switched from Krebs-Henseleit buffer to nicorandil or
nicorandil  glibenclamide containing buffer. During
ischemia, reduced depletion of ATP was found in hearts
treated with 103 M Nico. In the nitroglycerine-treated
hearts, there was no evidence for a reduced ATP deple-
tion during ischemia. Thus, this effect cannot be caused
by increased coronary ﬂow before ischemia. It is most
likely caused by K-channel activation. This mecha-
nism is supported by the fact that ATP degradation was
not reduced in hearts with blocked K channels, for ex-
ample, when treated with 103 M nicorandil  gliben-
clamide.
Low-dose nicorandil had no effect on ATP depletion.
Our ﬁnding is in contrast to the work of Gross et al. (43),
who reported that the loss of total adenine nucleotides
was prevented by 7 µM nicorandil at 30-min reperfusion
after 20 min of low-ﬂow ischemia. Recently published
work (44,45) in isolated cells suggests that low concen-
trations(10or100 µM)of nicorandilactivateonlythe mi-
tochondrial K channels, whereas high concentrations
(1000 µM) activate both mitochondrial and sarcolemmal
K channels. In contrast to isolated cells, in our model of
totalglobalischemiatheeffectsonmitochondrialorsarco-
lemmal K channels cannot be distinguished. Thus, the
reasons for these differences remain unclear at present.
Hearts treated with nicorandil at any concentration
showed reduced proton accumulation during ischemia.
Because this effect was not inﬂuenced by K-channel
blockade with glibenclamide,we conclude that the reduc-
tion of H accumulation is an effect of the nitro moiety
of nicorandil.
Adverse Effects of Nicorandil During
Ischemia-Reperfusion Injury
In hearts treated with high-dose nicorandil (103 M)
ventricular ﬁbrillation occurred during reperfusion. Be-
cause K-channel activators cause a shortening of the
action potential and attenuate membrane depolarization
(42,46), we speculate that the latter effect causes ventric-
ular ﬁbrillation. However, the concentration of nicorandil
used in our study was four orders in magnitude higher
than serum levels of nicorandil in patients. Therefore, the
direct clinical relevance of this ﬁnding remains uncertain.
Mechanisms of Nicorandil During
Ischemia-Reperfusion Injury
We conclude that the protective mechanisms of nico-
randil during ischemia are related to the simultaneous ac-
tion of both properties of the molecule. First, K-channel
activation during ischemia prevents ATP depletion in
hearts treated with high-dose (1000 µM) nicorandil. Sec-
ond, NO release and increased pre-ischemic coronary
ﬂow might weaken the accumulation of protons—and
thus the decrease of pH—during ischemia.
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